Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology
Disease Category: Gastroesophageal Reflux Disease (GERD)

Trial Information

The purpose of this study is to demonstrate that subjects with gastroesophageal reflux disease whose symptoms are well-controlled on twice daily proton pump inhibitors, remain well-controlled when switched to dexlansoprazole MR. Total participation time in this study is anticipated to be 12 weeks.

Gastroesophageal reflux disease is recognized as a common and persistent medical problem in the US adult population. Gastroesophageal reflux disease comprises a spectrum of acid-related disorders including symptomatic nonerosive gastroesophageal reflux disease and erosive esophagitis. It affects men and women in nearly equal proportions, and the severity and intensity of heartburn symptoms may be similar in both types of patients.

Dexlansoprazole modified release is a dual delayed release formulation that consists of two types of granules contained in a single capsule. This dual delayed release formulation is designed to extend the duration of drug exposure and maintain pharmacologically active levels over a longer time period.

The purpose of this study is to demonstrate that subjects with gastroesophageal reflux disease whose symptoms are well-controlled on twice daily proton pump inhibitors, remain well-controlled when switched to dexlansoprazole MR. Total participation time in this study is anticipated to be 12 weeks.

Patient Inclusion Criteria:

• Has a history of gastroesophageal reflux disease symptom, including heartburn, prior to therapy, who are currently being treated with twice daily proton pump inhibitors, excluding Kapidex (dexlansoprazole).
• Taking a stable dose of any twice daily proton pump inhibitors for less than or equal to 1 year and greater than 8 weeks prior to Screening.
• Participant is well-controlled on their current twice daily proton pump inhibitors.
• Females cannot be nursing and must have a negative urine pregnancy test at Day -1, be of non-childbearing potential and on an acceptable form of contraception, or have had bilateral tubal ligation if performed a minimum of 90 days prior to Day 1.

Patient Exclusion Criteria:

• Has a history of co-existing diseases affecting the esophagus, history of radiation therapy or cryotherapy to the esophagus, caustic or physiochemical trauma such as sclerotherapy to the esophagus.
• Has active gastric or duodenal ulcers during the 30 days prior to Screening.
• Has acute upper gastrointestinal hemorrhage during the 30 days prior to Screening.
• Has current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.
• Has known hypersensitivity to any proton pump inhibitor or any component of dexlansoprazole MR.
• Use of any H2RA or antacids during Screening or anticipated use during the study treatment period.
• Use of the following medications 7 days prior to Screening or anticipated use during the study:
  • Sucralfate.
  • Misoprostol.
  • Systemic corticosteroids.
  • Prokinetics (to include metoclopramide, cisapride, tegaserod).
  • Bisphosphonates during the 6 months prior to Screening or anticipated use during the study.
  • Chronic use of nonsteroidal anti-inflammatory drugs
  • Drugs with significant anticholinergic effects such as tricyclic antidepressants or drugs with central nervous system effects that could mask perception of symptoms.
  • Any investigational drug(s) within 30 days of Screening.
• Has received blood products within the 3 months prior to Screening.
• History of alcohol abuse or illegal drug use or drug addiction in the 12 months prior to Screening.
• Evidence of uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality, which may impact the ability of the subject to participate or potentially confound the study results.
• Atypical manifestations of gastroesophageal reflux disease.
• Has abnormal screening laboratory values that suggest a clinically significant underlying disease or condition.
• Cancer within 5 years prior to Screening.
• Is known to have acquired immunodeficiency syndrome.
• Has any condition that is likely to require inpatient surgery during the course of the study.
• Surgery of the acute upper gastrointestinal tract, including bariatric.
• Is in the opinion of the investigator unable to comply with the requirements of the study or are unsuitable for any reason.

Tim Davis, Site Manager
West Coast Research LLC
2301 Camino Ramon, Ste. 290
San Ramon, CA 94583
Phone: 925-413-1451
EMail: tdavis@westcoastresearch.com

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.